Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ODV vs RNA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ODV Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 8–2 Matrix Metrics)

ODV Overall Winner 6-Pillar Tally: ODV 3 – 2 RNA (1 Tie) Matrix Metrics: ODV 8 – 2 RNA

As of Nov 16, 2026, Osisko Development Corp. (ODV) is the stronger overall head-to-head candidate over Avidity Biosciences, Inc. (RNA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). ODV carries a Unified Composite Score of 56.2/100 (HOLD) at $2.27 (24.0x Forward P/E, -414.1% operating margin), whereas RNA carries 41.9/100 (SELL) at $6.43 (N/M Forward P/E, -194.8% operating margin).

  • Technical & Structure Timing Caution: ODV is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7); meanwhile RNA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ODV vs RNA
ODV NYSE Head-to-Head Winner
Osisko Development Corp.
Gold And Silver Ores
$2.27
+0.89% 1D
Market Cap $678.0M
TTM Revenue $38M
Forward P/E 24.0x
Beta / 30D Vol 2.13β · 45% Vol
Unified Composite Score
56.2 / 100 HOLD
Tech 25.0 Fund 45.0 Flow 50.0 Mom 68.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.2%), weak momentum, RSI 37
RSI-14: 36.7 · SMA20: $2.44 · SMA50: $2.68
RNA NASDAQ
Avidity Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$6.43
-14.38% 1D
Market Cap $162.0M
TTM Revenue $39M
Forward P/E N/M
Beta / 30D Vol 1.04β · 55% Vol
Unified Composite Score
41.9 / 100 SELL
Tech 16.0 Fund 44.0 Flow 61.0 Mom 65.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -19.8%), weak momentum, RSI 23
RSI-14: 22.5 · SMA20: $8.11 · SMA50: $8.49

6-Pillar Scorecard Institutional Category Breakdown (ODV 3 – 2 RNA)

Columns: Metric · ODV · RNA
1. Valuation Multiples ODV
Forward P/E 24.0x N/M
Trailing P/E 24.0x N/M
PEG Ratio N/M N/M
EV / Revenue 18.0x N/M
2. Growth & Scale ODV
Revenue Growth (YoY) +2638.5% +24.2%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $38M $39M
Market Cap $678.0M $162.0M
3. Profitability & Quality RNA
Gross Margin 61.5% -14.0%
Operating Margin -414.1% -194.8%
Net Profit Margin -189.6% -180.9%
Return on Equity (ROE) -12.4% -95.0%
4. Balance Sheet & Cash Flow ODV
Cash Generation (TTM) -$43M EBITDA -$73M
Cash Flow Margin -114.9% EBITDA Mgn N/A
Net Cash / Leverage $2.29 Book/Sh · -12.4% ROE $265M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning RNA
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 0.9% (2nd %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Gold Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ODV (8) vs RNA (2)
Institutional Metric ODV RNA Criterion Row Edge
Market Capitalization
Scale
$678.0M $162.0M Larger Scale ODV
Trailing P/E Ratio
Valuation
24.0x N/M Lower Multiple ODV
Forward P/E Ratio
Valuation
24.0x N/M Lower Multiple ODV
Revenue Growth (YoY)
Growth
+2638.5% +24.2% Higher Growth ODV
Operating Margin (TTM)
Profitability
-414.1% -194.8% Higher Margin RNA
Net Profit Margin
Profitability
-189.6% -180.9% Higher Margin RNA
Return on Equity (ROE)
Capital Efficiency
-12.4% -95.0% Higher ROE ODV
52-Week Range Position
Momentum
5% ($2–$5) 0% ($6–$73) Stronger Trend ODV
Beta / 30D Volatility
Risk Regime
2.13β · 45% Vol 1.04β · 55% Vol Lower Realized Risk ODV
Unified Institutional Score
Composite Signal
56.2 / 100 (HOLD) 41.9 / 100 (SELL) Higher Composite ODV
Trailing 12M Revenue (USD)
Operating Scale
$38M $39M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
61.5% -14.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 18.0x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$43M EBITDA ($2.29 Book/Sh · -12.4% ROE) -$73M ($265M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RNA +14.7 pp
ODV: -18.35% · RNA: -3.65%
3M Horizon RNA +19.24 pp
ODV: -32.64% · RNA: -13.4%
6M Horizon ODV +45.76 pp
ODV: -37.47% · RNA: -83.23%
1Y Horizon ODV +49.02 pp
ODV: -33.82% · RNA: -82.84%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ODV vs RNA. Trailing 12-month operating profitability (ODV -414.1% vs RNA -194.8%) and valuation multiples (ODV 24.0x vs RNA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ODV ADR TTM Benchmark FX-Normalized USD
TTM Revenue$38M
Gross Margin61.5%
Op. Margin-414.1%
ROE / Fwd P/E-12.4% · 24.0x
RNA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$39M
Gross Margin-14.0%
Op. Margin-194.8%
ROE / Fwd P/E-95.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ODV UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ODV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RNA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.9%
IV Percentile 2nd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RNA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ODV Moat Profile Cyclical / Execution-Driven Positioning
Gold Operator
Competes within the Gold value chain with $678.0M market capitalization and -414.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
RNA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $162.0M market capitalization and -194.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ODV vs RNA Key Questions & Quantitative Answers

As of Nov 16, 2026, Osisko Development Corp. (ODV) is the stronger overall head-to-head candidate over Avidity Biosciences, Inc. (RNA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). ODV carries a Unified Composite Score of 56.2/100 (HOLD) at $2.27 (24.0x Forward P/E, -414.1% operating margin), whereas RNA carries 41.9/100 (SELL) at $6.43 (N/M Forward P/E, -194.8% operating margin). Technical & Structure Timing Caution: ODV is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7); meanwhile RNA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ODV leads the Growth & Scale pillar: ODV posts +2638.5% YoY revenue growth and +0.0% YoY earnings growth on $38M TTM revenue (61.5% gross margin, -414.1% operating margin), compared with RNA at +24.2% YoY revenue growth and +0.0% YoY earnings growth on $39M TTM revenue (-14.0% gross margin, -194.8% operating margin). On trailing 12-month operating scale, ODV generates $38M in USD-normalized revenue versus $39M for RNA. In operating R&D and SG&A reinvestment, ODV deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RNA.

ODV screens cheaper on headline valuation multiples. ODV trades at 24.0x Forward P/E, 24.0x Trailing P/E, N/M PEG, and 18.0x EV/Revenue (-114.9% EBITDA margin), whereas RNA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ODV (-12.4% ROE) versus RNA (-95.0% ROE) capital efficiency.

In options market volatility and institutional positioning, ODV carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.13β · 45% Vol realized risk). By comparison, RNA carries 0.9% implied volatility (2nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.04β · 55% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.